ARS Pharmaceuticals Inc (NASDAQ: SPRY) on Friday, soared 5.58% from the previous trading day, before settling in for the closing price of $16.14. Within the past 52 weeks, SPRY’s price has moved between $3.38 and $17.08.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -34.76% over the past five years. The company achieved an average annual earnings per share of -9.21%. With a float of $49.21 million, this company’s outstanding shares have now reached $96.41 million.
Let’s look at the performance matrix of the company that is accounted for 26 employees. In terms of profitability, gross margin is 86.81%, operating margin of -12071.49%, and the pretax margin is -9536.81%.
ARS Pharmaceuticals Inc (SPRY) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of ARS Pharmaceuticals Inc is 49.24%, while institutional ownership is 40.37%. The most recent insider transaction that took place on Oct 16 ’24, was worth 200,000. In this transaction Chief Financial Officer of this company sold 12,500 shares at a rate of $16.00, taking the stock ownership to the 4,949 shares. Before that another transaction happened on Oct 15 ’24, when Company’s CHIEF MEDICAL OFFICER sold 100,000 for $14.88, making the entire transaction worth $1,487,595. This insider now owns 1,298,499 shares in total.
ARS Pharmaceuticals Inc (SPRY) Performance Highlights and Predictions
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.16 earnings per share (EPS) for the period topping the consensus outlook (set at -0.18) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.21% per share during the next fiscal year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
ARS Pharmaceuticals Inc (SPRY) is currently performing well based on its current performance indicators. A quick ratio of 32.78 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3488.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.47, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.75 in one year’s time.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
ARS Pharmaceuticals Inc (NASDAQ: SPRY) saw its 5-day average volume 1.04 million, a positive change from its year-to-date volume of 0.78 million. As of the previous 9 days, the stock’s Stochastic %D was 85.13%. Additionally, its Average True Range was 0.95.
During the past 100 days, ARS Pharmaceuticals Inc’s (SPRY) raw stochastic average was set at 99.58%, which indicates a significant increase from 98.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.03% in the past 14 days, which was lower than the 68.97% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.30, while its 200-day Moving Average is $10.56. Nevertheless, the first resistance level for the watch stands at $17.46 in the near term. At $17.88, the stock is likely to face the second major resistance level. The third major resistance level sits at $18.69. If the price goes on to break the first support level at $16.23, it is likely to go to the next support level at $15.42. Assuming the price breaks the second support level, the third support level stands at $15.00.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Key Stats
Market capitalization of the company is 1.74 billion based on 96,942K outstanding shares. Right now, sales total 30 K and income totals -54,370 K. The company made 500 K in profit during its latest quarter, and -12,520 K in sales during its previous quarter.
